Charles Schwab
AGL icon

Charles Schwab’s Agilon Health AGL Stock Holding History

Charles Schwab’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4M Sell
348,960
-15,539
-4% -$1.02M 0.01% 1438
2026
Q1 		$2.88M Buy
364,499
+43,739
+14% +$707K ﹤0.01% 2613
2025
Q4 		$5.52M Buy
320,760
+75,737
+31% +$1.47M ﹤0.01% 2403
2025
Q3 		$6.31M Buy
245,023
+46,187
+23% +$1.74M ﹤0.01% 2325
2025
Q2 		$11.4M Buy
198,836
+1,253
+0.6% +$100K ﹤0.01% 1948
2025
Q1 		$21.4M Buy
197,583
+15,921
+9% +$1.39M ﹤0.01% 1606
2024
Q4 		$8.63M Buy
181,662
+59,941
+49% +$3.62M ﹤0.01% 2080
2024
Q3 		$12M Sell
121,721
-6,854
-5% -$885K ﹤0.01% 1946
2024
Q2 		$21M Buy
128,575
+40,302
+46% +$5.74M ﹤0.01% 1651
2024
Q1 		$13.5M Buy
88,273
+14,407
+20% +$2.4M ﹤0.01% 1830
2023
Q4 		$23.2M Buy
73,866
+1,991
+3% +$721K 0.01% 1499
2023
Q3 		$31.9M Buy
71,875
+2,817
+4% +$1.27M 0.01% 1185
2023
Q2 		$29.9M Buy
69,058
+22,290
+48% +$12.5M 0.01% 1216
2023
Q1 		$27.8M Buy
46,768
+424
+0.9% +$237K 0.01% 1219
2022
Q4 		$18.7M Buy
46,344
+2,080
+5% +$975K 0.01% 1496
2022
Q3 		$25.9M Buy
44,264
+32,725
+284% +$19.6M 0.01% 1192
2022
Q2 		$6.3M Buy
11,539
+541
+5% +$274K ﹤0.01% 2087
2022
Q1 		$6.97M Buy
10,998
+303
+3% +$156K ﹤0.01% 2117
2021
Q4 		$7.22M Buy
10,695
+753
+8% +$458K ﹤0.01% 2168
2021
Q3 		$6.51M Buy
9,942
+1,046
+12% +$894K ﹤0.01% 2247
2021
Q2 		$9.02M Buy
+8,896
New +$7.79M ﹤0.01% 2058

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab's AGL Position: Q2 2026 in Review

Charles Schwab reduced its Agilon Health (AGL) stake by 4.3% in Q2 2026, selling an estimated $1.02M and leaving 348,960 shares worth $37.4M. The position accounts for 0.01% of the portfolio, ranked #1438.

Charles Schwab first reported a position in AGL in Q2 2021 and has held it in 21 quarters since. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • Charles Schwab held 348,960 shares of Agilon Health worth $37.4M as of Q2 2026.
  • Charles Schwab sold 15,539 Agilon Health shares in Q2 2026, an estimated $1.02M.
  • Agilon Health made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1438 holding.
  • Charles Schwab first reported a position in Agilon Health in Q2 2021 and has held it in 21 quarters since.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.